U.S. Uterine Fibroid Treatment Market, By Procedure Type (Endometrial Ablation, MRI Guided Procedures (MRI-guided Percutaneous Laser Ablation, MRI-guided Transcutaneous Focused Ultrasound), Hysterectomy (Abdominal Hysterectomy, Vaginal Hysterectomy, Lapar

U.S. Uterine Fibroid Treatment Market, By Procedure Type (Endometrial Ablation, MRI Guided Procedures (MRI-guided Percutaneous Laser Ablation, MRI-guided Transcutaneous Focused Ultrasound), Hysterectomy (Abdominal Hysterectomy, Vaginal Hysterectomy, Laparoscopic Hysterectomy, Robotic Hysterectomy, Hysteroscopic Morcellation), Myomectomy (Open Myomectomy, Laparoscopic Myomectomy, Robotic Myomectomy), Uterine Artery Embolization, Radiofrequency Ablation, Others), By End User (Hospitals, Ambulatory Surgical Centers) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Uterine fibroid is the benign tumor of the woman’s uterus formed of smooth muscle that are found on the wall of the uterus i.e within the wall of uterine wall or can attach to the uterine wall. Uterine fibroid grow as a single tumor or in clusters and these uterine fibroid can lead to pelvic pain, excessive menstrual bleeding, and frequent urination. Uterine fibroids majorly develop in 50% of women, which have led to increased rate of hysterectomy i.e. removal of the uterus. Uterine fibroid is developed in women that often have a family history of fibroids. The uterine fibroid is formed and grown in response to the stimulation by hormone estrogen that is produced naturally in the body. Various types of uterine fibroid treatment are available in the market due to technological advancements, which include minimal invasive surgical treatment that help to control the growth of uterine fibroid. Uterine fibroid can be treated by both surgery and medications, the surgery include for treatment of uterine fibroid are hysterectomy, cryosurgery, myomectomy, uterine artery embolization, and MRI-guided high-intensity focused ultrasound.
Restraints of the U.S. Uterine Fibroid Treatment Market
Major factors hampering the growth of the U.S. uterine fibroid treatment market during the forecast period constitutes of risks associated with the use of morcellators, and high treatment costs.
Key features of the study:
This report provides in-depth analysis of the U.S. uterine fibroid treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the U.S. uterine fibroid treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The U.S. uterine fibroid treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the assistive reproductive technology market.
Detailed Segmentation
U.S. Uterine Fibroid Treatment Market, By Procedure Type:
Endometrial Ablation
MRI Guided Procedures
MRI-guided Percutaneous Laser Ablation
MRI-guided Transcutaneous Focused Ultrasound
Hysterectomy
Abdominal Hysterectomy
Vaginal Hysterectomy
Laparoscopic Hysterectomy
Robotic Hysterectomy
Hysteroscopic Morcellation
Myomectomy
Open Myomectomy
Laparoscopic Myomectomy
Robotic Myomectomy
Uterine Artery Embolization
Radiofrequency Ablation
Others
U.S. Uterine Fibroid Treatment Market, By End User:
Hospitals
Ambulatory Surgical Centers
Company Profiles
Blue Endo*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Boston Scientific Corporation
CooperSurgical, Inc.
KARL STORZ SE & Co. KG
Myovant Sciences (Sumitovant Biopharma Ltd.)
Halt Medical, Inc.
LiNA Medical USA
Merit Medical Systems
Olympus Corporation
Richard Wolf GmbH
“*” marked represents similar segmentation in other categories in the respective section.